New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
18:33 EDTEXPR, CPST, OCLS, JDSU, FNSR, XEC, AMD, INTC, NKTR, ARO, AXASOn The Fly: After Hours Movers
HIGHER: Express (EXPR), up 21.33% after Sycamore Partners seeks to acquire remaining shares... Aeropostale (ARO), up 7.78%... Nektar Therapeutics (NKTR), up 10.77% after AADPAC voted that the FDA should not require cardiovascular outcomes trials for the peripherally-acting mu-opioid receptor antagonist class of drugs... Intel (INTC), up 5.33% after raising quarterly and fiscal 2014 outlook... Advanced Micro Devices (AMD), up 2.1%... Cimarex Energy (XEC), up 1.5%. DOWN AFTER EARNINGS: Finisar (FNSR), down 21.8% after reporting quarterly results... JDS Uniphase (JDSU), down 3.47%... Oculus (OCLS), down 2.74% after reporting fourth quarter results... Capstone Turbine (CPST), down 1.9%. ALSO LOWER: Abraxas Petroleum (AXAS), down 1.35% after commencing a 10M share common stock offering.
News For EXPR;ARO;NKTR;INTC;AMD;XEC;FNSR;JDSU;OCLS;CPST;AXAS From The Last 14 Days
Check below for free stories on EXPR;ARO;NKTR;INTC;AMD;XEC;FNSR;JDSU;OCLS;CPST;AXAS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 25, 2014
19:49 EDTXECCimarex Energy agrees to sell $326M of oil, gas assets
Subscribe for More Information
10:50 EDTOCLSOculus receives FDA 510(k) clearance for root canal solution
The FDA decided the product was Substantially Equivalent on August 18, according to a post on the agency's website. Reference Link
08:33 EDTCPSTCapstone Turbine receives 5.5MW order from BPC Engineering
Subscribe for More Information
06:30 EDTINTCIntel, Chunghwa Telecom sign cooperation MOU for IoT, DigiTimes reports
Subscribe for More Information
06:24 EDTFNSRFinisar September volatility elevated into Q1 and outlook
Subscribe for More Information
August 24, 2014
21:56 EDTINTC, JDSUB. Riley to hold a tour
Silicon Valley Tech Tour travels throughout Silicon Valley on August 25-27.
August 22, 2014
09:05 EDTAROOn The Fly: Pre-market Movers
UP AFTER EARNINGS: GameStop (GME), up 7.1%... Foot Locker (FL), up 3%... Qunar (QUNR), up 6.9%... The Fresh Market (TFM), up 6.5%... Ross Stores (ROST), up 3.8%. ALSO HIGHER: El Pollo Loco (LOCO), up 5.3% after signing franchisee to 20 unit expansion agreement in Texas... Gap (GPS), up 2.8% after upgraded at Janney Capital following Q2 results above analyst estimates and announcing plans to open the first franchise-operated Gap stores in India in 2015. DOWN AFTER EARNINGS: Aeropostale (ARO), down 8%... Ann Inc (ANN), down 2.7%. ALSO LOWER: Ampio (AMPE), down 4.4% after downgraded at Jefferies...
06:20 EDTAROOptions expected to be active
Options expected to be active: GME ARO CRM INTU TFM MRVL ROST BRCD
August 21, 2014
18:22 EDTAROOn The Fly: After Hours Movers
Subscribe for More Information
16:09 EDTAROAeropostale sees Q3 EPS (44c)-(48c), consensus (33c)
The effective tax rate for Q3 is projected to be approximately 4.0%. This outlook does not include the impact of any store impairments or accelerated store closure costs which may be identified, consulting fees, and severance costs related to the company's previous CEO.
16:08 EDTAROAeropostale reports Q2 EPS ex-charges (46c), consensus (49c)
Subscribe for More Information
15:37 EDTNKTRNektar: Baxter announces positive results from Phase 3 study of BAX 855
Nektar Therapeutics (NKTR) reports Baxter International (BAX) announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII treatment for hemophilia A based on ADVATE, which met its primary endpoint in reducing annualized bleed rates in the prophylaxis arm compared to the on-demand arm. Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. Patients in a twice-weekly prophylaxis arm experienced a 95 percent reduction in median ABR as compared to those in the on-demand arm (1.9 vs. 41.5, respectively). BAX 855 was also effective in treating bleeding episodes, 96 percent of which were controlled with one or two infusions. The half-life of BAX 855 was 1.4 - 1.5 times that of ADVATE, consistent with the findings from the Phase 1 study. No patients developed inhibitors to BAX 855 and no treatment-related serious adverse events, including hypersensitivity, were reported. The most common product-related adverse event was headache. Baxter expects to submit a Biologics License Application for BAX 855 to the U.S. Food and Drug Administration before the end of 2014 and will present additional data in the coming months. In addition to an ongoing continuation study for patients who have completed the pivotal trial, the company is initiating a Phase 3, prospective, open-label, multi-center study to evaluate the safety and efficacy of BAX 855 among 60 previously treated patients under the age of 12 with severe hemophilia A. Consistent with guidelines published by the European Medicines Agency that require a study in children less than 12 years of age prior to filing, Baxter expects to file a Marketing Authorization Application with the EMA upon the completion of the pediatric study
15:15 EDTARONotable companies reporting after market close
Subscribe for More Information
08:43 EDTCPSTCapstone Turbine announces follow-on order for 75 C65s from Horizon Power
Capstone Turbine announced that it received an order for seventy five C65 microturbines, scheduled for shipment through December 2014, from Horizon Power Systems for several U.S. Oil and Gas Customers. The order was placed by Horizon Power Systems, Capstone's distributor for the Eagle Ford, Permian, Barnett, Mancos, San Juan, and Wattenberg shale plays. Recognizing Capstone's demonstrated success in oil and gas operations, multiple customers are again choosing clean and green microturbine technology to power their production and compression operations. This order will expand Horizon's fleet to approximately 700 Capstone microturbines, the majority of which serve the demanding oil and gas market. The microturbines will provide prime power and serve all stages of oil and gas production including central processing station power, wellhead operation, transmission, and flare reduction.
August 20, 2014
13:05 EDTINTCIntel and Unity collaborate to extend Android support across Intel-based devices
Subscribe for More Information
August 19, 2014
11:53 EDTAROAeropostale soars as Geiger returns as CEO
Subscribe for More Information
10:49 EDTAROAeropostale breaks out as Geiger returns as CEO
The $3.50 level has been the top of the trading range, a base, since June of this year. With price currently at $3.80, the shares have bullishly broken out of the range. Longer base breakouts typically persist for some time following the break. At current price next resistance is at $3.98. Support is at $3.50. For the breakout to remain valid, share price needs to close today well above that $3.50 mark.
09:07 EDTAROOn The Fly: Pre-market Movers
Subscribe for More Information
08:42 EDTCPSTCapstone Turbine expands CHP footprint in Russian manufacturing sector
Subscribe for More Information
06:56 EDTAROAeropostale CEO change may not help much, says Wells Fargo
After Aeropostale announced that its longtime former CEO, Julian Geiger, would return to the role, Wells Fargo thinks that Geiger may not be able to solve the company's positioning problems. According to the firm, the company was known for providing basics, but consumers are not willing to pay for basics anymore. The firm keeps a Market Perform rating on the shares.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use